Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

TAVR still a safe treatment option for immunocompromised patients
While patients with a weakened immune system are still more likely to die after TAVR than other patients, those deaths are largely not related to the procedure or any other cardiovascular issues. This new meta-analysis explored data from a variety of clinical trials.
Pope welcomes cardiologists to Vatican City
Pope Leo XIV told interventional cardiologists their work “stands at the crossroads of science, compassion and ethical responsibility.” When they treat patients, he added, they are treating the heart “both physically and metaphorically, bringing relief to those who suffer.”
Edwards Lifesciences shares positive outlook for 2026, pointing to continued importance of TAVR
The company expects TAVR sales alone to be as high as $4.9 billion in 2026. Other minimally invasive therapies are projected to make a major impact as well.
FDA commissioner claims Biden administration hid heart risks of COVID-19 vaccines from public
The allegation came days after an internal FDA memo linked the vaccines to the deaths of multiple children. A group of former FDA commissioners pushed back against the content of that memo.
Community Health Systems sells ambulatory diagnostics segment to Labcorp for $194M
The all-cash deal is expected to be finalized in April 2026. With this divestment of its ambulatory labs, Tennessee-based Community Health Systems said it will be better able to focus on its core patient care business.

High Lp(a) levels increase risk of repeat cardiovascular events—LDL drugs may help

Researchers evaluated data from more than 273,000 patients with a history of ASCVD, noting that higher Lp(a) levels are consistently linked to worse cardiovascular outcomes.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

Answering key follow-up questions after the FDA approved TAVR in asymptomatic patients

The approval of certain TAVR valves to be used in asymptomatic patients is expected to make a significant impact on patient care going forward.

Stenting ‘an important treatment option’ for PCI patients with complete blockages

The study's lead author emphasized that stenting during CTO PCI procedures "should be considered safe and effective in the long term."

PET imaging reveals long-term heart and lung damage from COVID-19

New data highlight the long-lasting effects of the coronavirus, revealing changes that are not detectable by standard medical assessments.

Smaller LV dimensions may increase risk of death for HeartMate 3 LVAD patients

Researchers tracked short- and long-term data from nearly 2,000 patients, presenting their findings in JACC: Heart Failure.

World’s first leadless LBBAP procedures linked to ‘promising’ outcomes

Cardiologists are turning to leadless pacemakers more and more for cardiac pacing, but those devices have not previously been able to perform LBBAP. This new analysis includes new data on the world’s very first leadless LBBAP procedures.

tirzepatide injections Zepbound Eli Lilly

Tirzepatide bests semaglutide in patients with type 2 diabetes, kidney disease and heart failure

Researchers examined data from more than 9,000 patients, sharing their findings at SCAI 2025.

AI predicts LBBB risk in TAVR patients prior to treatment

The authors tested out a variety of machine learning techniques, including large language models and more traditional algorithms. They focused on data that can be gathered prior to treatment, ensuring cardiologists know as much as possible before the procedure.

Clinical

TAVR still a safe treatment option for immunocompromised patients

Pope welcomes cardiologists to Vatican City

Edwards Lifesciences shares positive outlook for 2026, pointing to continued importance of TAVR

FDA commissioner claims Biden administration hid heart risks of COVID-19 vaccines from public

Community Health Systems sells ambulatory diagnostics segment to Labcorp for $194M